Yili Chuanning BiotechnologyLtd Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
Yili Chuanning BiotechnologyLtd has a total shareholder equity of CN¥7.6B and total debt of CN¥1.4B, which brings its debt-to-equity ratio to 18.6%. Its total assets and total liabilities are CN¥10.6B and CN¥3.0B respectively. Yili Chuanning BiotechnologyLtd's EBIT is CN¥1.7B making its interest coverage ratio 33.7. It has cash and short-term investments of CN¥624.8M.
Belangrijke informatie
18.6%
Verhouding schuld/eigen vermogen
CN¥1.41b
Schuld
| Rente dekkingsratio | 33.7x |
| Contant | CN¥624.79m |
| Aandelen | CN¥7.59b |
| Totaal verplichtingen | CN¥2.96b |
| Totaal activa | CN¥10.55b |
Recente financiële gezondheidsupdates
These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely
Oct 11
We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease
May 31Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt
Feb 26Recent updates
These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely
Oct 11If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity
Jul 23We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease
May 31Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt
Feb 26Analyse van de financiële positie
Kortlopende schulden: 301301's short term assets (CN¥4.1B) exceed its short term liabilities (CN¥2.0B).
Langlopende schulden: 301301's short term assets (CN¥4.1B) exceed its long term liabilities (CN¥965.2M).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: 301301's net debt to equity ratio (10.4%) is considered satisfactory.
Schuld verminderen: 301301's debt to equity ratio has reduced from 106.6% to 18.6% over the past 5 years.
Schuldendekking: 301301's debt is well covered by operating cash flow (75.4%).
Rentedekking: 301301's interest payments on its debt are well covered by EBIT (33.7x coverage).